The multidrug resistance proteins Pgp, MRP, and BCRP as markers for lowering the efficacy of tamoxifen in the treatment of breast cancer
The antiestrogen tamoxifen was examined for its effect on the interaction of monoclonal antibodies with the multidrug resistance markers: with Pgp and MRP1 in the cultured T-lymphoblast leukemia cell line Jurkat and with BCRP in the cultured cervical cancer cell line HeLa. The investigation used imm...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2014-07-01
|
| Series: | Опухоли женской репродуктивной системы |
| Subjects: | |
| Online Access: | https://ojrs.abvpress.ru/ojrs/article/view/136 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849403729388765184 |
|---|---|
| author | T. A. Bogush E. A. Dudko E. A. Bogush B. E. Polotsky S. A. Tyulyandin M. I. Davydov |
| author_facet | T. A. Bogush E. A. Dudko E. A. Bogush B. E. Polotsky S. A. Tyulyandin M. I. Davydov |
| author_sort | T. A. Bogush |
| collection | DOAJ |
| description | The antiestrogen tamoxifen was examined for its effect on the interaction of monoclonal antibodies with the multidrug resistance markers: with Pgp and MRP1 in the cultured T-lymphoblast leukemia cell line Jurkat and with BCRP in the cultured cervical cancer cell line HeLa. The investigation used immunofluorescence and flow cytofluorimetric assays, primary monoclonal and isotypic antibodies labeled with the fluorescent dyes FITS and PE. After tamoxifen use, there was an increase in specific fluorescence and the number of specifically fluorescent cells on incubation with Pgp and BCRP antibodies and a reduction in those on incubation with MRP1 antibodies. This directly indicates that tomoxifen binds to Pgp, BCRP, and MRP1, which inevitably results in a decrease in the intracellular concentration of the antiestrogen available for the interaction with other cellular targets, including that with estrogen receptors. The authors consider that there is every reason to consider Pgp, BCRP, and MRP1 as markers for lowering the efficacy of tamoxifen in the treatment of breast cancer with the positive estrogen receptor status. |
| format | Article |
| id | doaj-art-fab5e624342a49eba5cd663e2402dbc4 |
| institution | Kabale University |
| issn | 1994-4098 1999-8627 |
| language | Russian |
| publishDate | 2014-07-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Опухоли женской репродуктивной системы |
| spelling | doaj-art-fab5e624342a49eba5cd663e2402dbc42025-08-20T03:37:11ZrusABV-pressОпухоли женской репродуктивной системы1994-40981999-86272014-07-010181810.17650/1994-4098-2011-0-1-8-18152The multidrug resistance proteins Pgp, MRP, and BCRP as markers for lowering the efficacy of tamoxifen in the treatment of breast cancerT. A. Bogush0E. A. Dudko1E. A. Bogush2B. E. Polotsky3S. A. Tyulyandin4M. I. Davydov5N.N. Blokhin Russian Cancer Research Cancer, Russian Academy of Medical Sciences, MoscowN.N. Blokhin Russian Cancer Research Cancer, Russian Academy of Medical Sciences, MoscowN.N. Blokhin Russian Cancer Research Cancer, Russian Academy of Medical Sciences, MoscowN.N. Blokhin Russian Cancer Research Cancer, Russian Academy of Medical Sciences, MoscowN.N. Blokhin Russian Cancer Research Cancer, Russian Academy of Medical Sciences, MoscowN.N. Blokhin Russian Cancer Research Cancer, Russian Academy of Medical Sciences, MoscowThe antiestrogen tamoxifen was examined for its effect on the interaction of monoclonal antibodies with the multidrug resistance markers: with Pgp and MRP1 in the cultured T-lymphoblast leukemia cell line Jurkat and with BCRP in the cultured cervical cancer cell line HeLa. The investigation used immunofluorescence and flow cytofluorimetric assays, primary monoclonal and isotypic antibodies labeled with the fluorescent dyes FITS and PE. After tamoxifen use, there was an increase in specific fluorescence and the number of specifically fluorescent cells on incubation with Pgp and BCRP antibodies and a reduction in those on incubation with MRP1 antibodies. This directly indicates that tomoxifen binds to Pgp, BCRP, and MRP1, which inevitably results in a decrease in the intracellular concentration of the antiestrogen available for the interaction with other cellular targets, including that with estrogen receptors. The authors consider that there is every reason to consider Pgp, BCRP, and MRP1 as markers for lowering the efficacy of tamoxifen in the treatment of breast cancer with the positive estrogen receptor status.https://ojrs.abvpress.ru/ojrs/article/view/136tamoxifenmultidrug resistance proteinspgpmrp1bcrpbreast cancerpredictive markers |
| spellingShingle | T. A. Bogush E. A. Dudko E. A. Bogush B. E. Polotsky S. A. Tyulyandin M. I. Davydov The multidrug resistance proteins Pgp, MRP, and BCRP as markers for lowering the efficacy of tamoxifen in the treatment of breast cancer Опухоли женской репродуктивной системы tamoxifen multidrug resistance proteins pgp mrp1 bcrp breast cancer predictive markers |
| title | The multidrug resistance proteins Pgp, MRP, and BCRP as markers for lowering the efficacy of tamoxifen in the treatment of breast cancer |
| title_full | The multidrug resistance proteins Pgp, MRP, and BCRP as markers for lowering the efficacy of tamoxifen in the treatment of breast cancer |
| title_fullStr | The multidrug resistance proteins Pgp, MRP, and BCRP as markers for lowering the efficacy of tamoxifen in the treatment of breast cancer |
| title_full_unstemmed | The multidrug resistance proteins Pgp, MRP, and BCRP as markers for lowering the efficacy of tamoxifen in the treatment of breast cancer |
| title_short | The multidrug resistance proteins Pgp, MRP, and BCRP as markers for lowering the efficacy of tamoxifen in the treatment of breast cancer |
| title_sort | multidrug resistance proteins pgp mrp and bcrp as markers for lowering the efficacy of tamoxifen in the treatment of breast cancer |
| topic | tamoxifen multidrug resistance proteins pgp mrp1 bcrp breast cancer predictive markers |
| url | https://ojrs.abvpress.ru/ojrs/article/view/136 |
| work_keys_str_mv | AT tabogush themultidrugresistanceproteinspgpmrpandbcrpasmarkersforloweringtheefficacyoftamoxifeninthetreatmentofbreastcancer AT eadudko themultidrugresistanceproteinspgpmrpandbcrpasmarkersforloweringtheefficacyoftamoxifeninthetreatmentofbreastcancer AT eabogush themultidrugresistanceproteinspgpmrpandbcrpasmarkersforloweringtheefficacyoftamoxifeninthetreatmentofbreastcancer AT bepolotsky themultidrugresistanceproteinspgpmrpandbcrpasmarkersforloweringtheefficacyoftamoxifeninthetreatmentofbreastcancer AT satyulyandin themultidrugresistanceproteinspgpmrpandbcrpasmarkersforloweringtheefficacyoftamoxifeninthetreatmentofbreastcancer AT midavydov themultidrugresistanceproteinspgpmrpandbcrpasmarkersforloweringtheefficacyoftamoxifeninthetreatmentofbreastcancer AT tabogush multidrugresistanceproteinspgpmrpandbcrpasmarkersforloweringtheefficacyoftamoxifeninthetreatmentofbreastcancer AT eadudko multidrugresistanceproteinspgpmrpandbcrpasmarkersforloweringtheefficacyoftamoxifeninthetreatmentofbreastcancer AT eabogush multidrugresistanceproteinspgpmrpandbcrpasmarkersforloweringtheefficacyoftamoxifeninthetreatmentofbreastcancer AT bepolotsky multidrugresistanceproteinspgpmrpandbcrpasmarkersforloweringtheefficacyoftamoxifeninthetreatmentofbreastcancer AT satyulyandin multidrugresistanceproteinspgpmrpandbcrpasmarkersforloweringtheefficacyoftamoxifeninthetreatmentofbreastcancer AT midavydov multidrugresistanceproteinspgpmrpandbcrpasmarkersforloweringtheefficacyoftamoxifeninthetreatmentofbreastcancer |